Kelsey Goodwin

Kelsey Goodwin is a director and senior research analyst at Piper Sandler covering the biotechnology sector. Prior to joining Piper Sandler in June 2025, Goodwin spent nearly seven years at Guggenheim Securities where she was a research analyst covering the oncology sector. Prior to making the transition to Wall Street, Goodwin was a healthcare consultant for IMS Health (now IQVIA) where she worked with many of the world's leading pharmaceutical companies. Goodwin received a bachelor's degree in biology from Bowdoin College.

Universe Coverage

Biotechnology
BCAX	Bicara Therapeutics, Inc.
BDTX	Black Diamond Therapeutics, Inc.
CGON	CG Oncology, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
JANX	Janux Therapeutics, Inc.
NUVL	Nuvalent, Inc.
RVMD	Revolution Medicines, Inc.
SMMT	Summit Therapeutics, Inc.
TNGX	Tango Therapeutics, Inc.
URGN	UroGen Pharma Ltd.